Literature DB >> 26775669

The Effectiveness of Influenza Vaccination in Different Groups.

Angela Domínguez1,2, Pere Godoy2,3, Nuria Torner1,2,3.   

Abstract

Annual administration of the seasonal influenza vaccine, especially to persons known to be at elevated risk for developing serious complications, is the focus of current efforts to reduce the impact of influenza. The main factors influencing estimated inactivated influenza vaccine efficacy and effectiveness, the results obtained in different population groups, current vaccination strategies and the possible advantages of new vaccines are discussed. The available evidence suggests that influenza vaccines are less effective in the elderly than in young adults, but vaccination is encouraged by public health institutions due to higher mortality and complications. There is no consensus on universal vaccination of children yet economic studies suggest that yearly paediatric vaccination is cost saving. The benefits of herd immunity generated by paediatric vaccination require further study. Newer vaccines should be more and more-broadly protective, stable, easy to manufacture and administer and highly immunogenic across all population groups.

Entities:  

Keywords:  Influenza vaccines; effectiveness; efficacy; risk groups; study design; vaccination policies

Mesh:

Substances:

Year:  2016        PMID: 26775669     DOI: 10.1586/14760584.2016.1142878

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  13 in total

Review 1.  Factors affecting immune responses to the influenza vaccine.

Authors:  Maria R Castrucci
Journal:  Hum Vaccin Immunother       Date:  2017-07-21       Impact factor: 3.452

Review 2.  Factors influencing the immunogenicity of influenza vaccines.

Authors:  Simin Wen; Zhengyu Wu; Shuyi Zhong; Mao Li; Yuelong Shu
Journal:  Hum Vaccin Immunother       Date:  2021-03-11       Impact factor: 3.452

3.  Knowledge of and Attitudes to Influenza Vaccination among Community Pharmacists in Catalonia (Spain). 2013-2014 Season: A Cross Sectional Study.

Authors:  Diana Toledo; Núria Soldevila; Rafel Guayta-Escolies; Pau Lozano; Pilar Rius; Pilar Gascón; Angela Domínguez
Journal:  Int J Environ Res Public Health       Date:  2017-07-11       Impact factor: 3.390

4.  Maternal antibodies protect offspring from severe influenza infection and do not lead to detectable interference with subsequent offspring immunization.

Authors:  Joan E M van der Lubbe; Jessica Vreugdenhil; Sarra Damman; Joost Vaneman; Jaco Klap; Jaap Goudsmit; Katarina Radošević; Ramon Roozendaal
Journal:  Virol J       Date:  2017-06-26       Impact factor: 4.099

5.  Distinct Effects of Monophosphoryl Lipid A, Oligodeoxynucleotide CpG, and Combination Adjuvants on Modulating Innate and Adaptive Immune Responses to Influenza Vaccination.

Authors:  Eun-Ju Ko; Young-Tae Lee; Youri Lee; Ki-Hye Kim; Sang-Moo Kang
Journal:  Immune Netw       Date:  2017-10-19       Impact factor: 6.303

6.  Integrating molecular point-of-care testing for influenza into primary care: a mixed-methods feasibility study.

Authors:  Simon de Lusignan; Uy Hoang; Harshana Liyanage; Manasa Tripathy; Ivelina Yonova; Rachel Byford; Filipa Ferreira; Javier Diez-Domingo; Tristan Clark
Journal:  Br J Gen Pract       Date:  2020-07-30       Impact factor: 5.386

7.  Injectable Excipients as Novel Influenza Vaccine Adjuvants.

Authors:  Huapeng Feng; Makoto Yamashita; Tiago Jose da Silva Lopes; Tokiko Watanabe; Yoshihiro Kawaoka
Journal:  Front Microbiol       Date:  2019-01-24       Impact factor: 5.640

8.  A Glycolipid Adjuvant, 7DW8-5, Enhances the Protective Immune Response to the Current Split Influenza Vaccine in Mice.

Authors:  Huapeng Feng; Noriko Nakajima; Li Wu; Makoto Yamashita; Tiago J S Lopes; Moriya Tsuji; Hideki Hasegawa; Tokiko Watanabe; Yoshihiro Kawaoka
Journal:  Front Microbiol       Date:  2019-09-18       Impact factor: 5.640

9.  Feasibility of Point-of-Care Testing for Influenza Within a National Primary Care Sentinel Surveillance Network in England: Protocol for a Mixed Methods Study.

Authors:  Simon de Lusignan; Uy Hoang; Harshana Liyanage; Ivelina Yonova; Filipa Ferreira; Javier Diez-Domingo; Tristan Clark
Journal:  JMIR Res Protoc       Date:  2019-11-11

10.  Enhancement of cutaneous immunity during aging by blocking p38 mitogen-activated protein (MAP) kinase-induced inflammation.

Authors:  Milica Vukmanovic-Stejic; Emma S Chambers; Mayte Suárez-Fariñas; Daisy Sandhu; Judilyn Fuentes-Duculan; Neil Patel; Elaine Agius; Katie E Lacy; Carolin T Turner; Anis Larbi; Veronique Birault; Mahdad Noursadeghi; Neil A Mabbott; Malcolm H A Rustin; James G Krueger; Arne N Akbar
Journal:  J Allergy Clin Immunol       Date:  2017-11-17       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.